Paolo Di Giorgio
CEO
Works at Angelini Ventures
Investor profile | Builders Republic
About
CEO of Angelini Ventures in Rome, Paolo Di Giorgio invests in Series A and Series B with check sizes ranging from €0.3 to €5 million, with a specialized thesis in biotech and therapeutics. His portfolio includes Arclight Therapeutics, GenEp, and Pretzel Therapeutics, where he serves as a Board Observer. Before joining the VC, he led R&D and external innovation at Angelini Pharma for five years, following a stint in Business Development at Novartis. His scientific background includes a PhD and a postdoc at Harvard University, as well as a postdoc at the Salk Institute for Biological Studies.
Profile
- Role
- CEO
- Fund
- Angelini Ventures
- Nationality
- Italian